drugset / Trial / NCT06219941
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2 .
Timeline
- Start
- 2023-12-13
- Primary completion
- 2026-11-17
- Completion
- 2027-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Irinotecan | Small molecule | — | — |
| Subject | L-LEUCOVORIN | Unknown | — | — |
| Subject | Leucovorin | Small molecule | — | — |
| Subject | Nanoliposomal Irinotecan | Unknown | — | — |
| Subject | Sonesitatug Vedotin | Other / unclassified | — | Intravenous |
| Subject | fluorouracil | Small molecule | — | — |